Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
Ontology highlight
ABSTRACT: This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.
DISEASE(S): Colorectal Neoplasms Malignant,Colorectal Neoplasms,Neoplasms
PROVIDER: 2398166 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA